PRESS RELEASE SUMMIT, N.J several month more info . & SEATTLE—-Celgene Corporation and Juno Therapeutics, Inc. announced today a worldwide collaboration for the advancement and commercialization of immunotherapies. Both businesses will leverage T cell therapeutic strategies to develop treatments for individuals with tumor and autoimmune diseases with an initial focus on Chimeric Antigen Receptor Technology and T Cell Receptor technologies. This deal strengthens Celgene’s placement in the transformative and emerging area of immuno-oncology, said Bob Hugin, Chairman and CEO of Celgene.
enzyme 5-alpha reductase
Like-for-like revenues rose 9.2 percent over 12 months, and 8.9 percent year on year in the fourth quarter. Cegedim Activ is #1 1 in solutions and software for the personal insurance industry. It continues to provide numerous industrial successes and top-notch operating performances, therefore demonstrating that its services and software offerings are well suited to its market. Its new multi-plan platform, ACTIV’RO, is already named the industry standard Product sales momentum in the sector offers been strong for the past year and will probably remain so for the coming quarters. It is also worth noting the continuing strong product sales momentum at Cegedim SRH, the professional in outsourced payroll and HR management services.